CAP TODAY/Amgen Webinar: FGFR2b Protein Overexpression: An Emerging IHC-Based Biomarker in G/GEJ Cancer

Thank you

This live web event has ended. Thank you for attending.

Description



FGFR2b Protein Overexpression:
An Emerging IHC-Based
Biomarker in G/GEJ Cancer
An MDT Perspective on a New Direction

Why should you register now for this webinar?
 In the era of precision medicine, biomarkers are emerging to have clinical importance for the diagnosis, treatment, and prognosis of advanced/metastatic G/GEJ cancers.

Join us for a dynamic panel discussion with a multidisciplinary team to:

  • Review the shift from histology-based to biomarker-driven treatment plans
  • Understand the prevalence and significance of FGFR2b protein overexpression as an emerging IHC-based biomarker in advanced/metastatic G/GEJ cancer
  • Discuss how FGFR2b protein overexpression can be detected by IHC
  • Discuss MDT considerations for optimizing advanced/metastatic G/GEJ cancer diagnostic and biomarker testing workflows
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Presenters: Yan Ji, MD, PhD, MS, Anthony Magliocco, MD, and Shaffer Mok, MD, MBS

What will this webinar empower you to do?
  • Describe the burden and challenges of advanced/metastatic G/GEJ cancer
  • Understand the full patient journey from diagnosis to treatment for patients with advanced/metastatic G/GEJ cancer
  • Recognize the role of FGFR2b protein overexpression as an emerging IHC-based biomarker
  • Consider optimized diagnostic and testing workflows to support appropriate patient access to biomarker-driven treatment plans for patients with advanced/metastatic G/GEJ cancer
FGFR2b, fibroblast growth factor receptor 2, isoform IIIb; G/GEJ, gastric/gastroesophageal junction; IHC, immunohistochemistry; MDT, multidisciplinary
CAP TODAY does not endorse any of the products or services named within.
Sponsored by Amgen
USA-OCF-82627

Contributors

  • Yan Ji, MD, PhD, MS

    Medical Oncologist, Health Partners
    Assistant Professor, University of Minnesota
    Principal Investigator, Metro-MN NCORP

  • Anthony Magliocco, MD

    President and CEO
    Protean BioDiagnostics
    Professor, Pathology and Oncology
    University of Central Florida

  • Shaffer Mok, MD, MBS

    Associate Professor; Program Director,
    Therapeutic Endoscopy Fellowship
    Director, Pancreas Interception Center
    Moffitt Cancer Center

  • Bob McGonnagle

    Publisher, CAP TODAY

December 12, 2024
Thu 1:00 PM EST

Duration 1H 0M

This live web event has ended.

For Technical Support
[email protected]